Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/297046
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Propranolol: a “pick and roll” team player in benign tumors and cancer therapies |
Autor: | Albiñana, Virginia CSIC; Gallardo-Vara, Eunate CSIC ORCID; Casado-Vela, Juan CSIC ORCID CVN; Recio-Poveda, Lucía ; Botella, Luisa María CSIC ORCID ; Cuesta, Ángel M. CSIC ORCID | Palabras clave: | Beta-adrenergic receptor antagonist Propranolol Chemotherapy Combination cancer therapy HIF Apoptosis Inflammation Angiogenesis Biomarker |
Fecha de publicación: | 4-ago-2022 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Journal of Clinical Medicine 11 (15) 4539 (2022) | Resumen: | Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies. | Descripción: | 18 p.-4 fig.-1 tab. | Versión del editor: | https://doi.org/10.3390/jcm11154539 | URI: | http://hdl.handle.net/10261/297046 | DOI: | 10.3390/jcm11154539 | E-ISSN: | 2077-0383 |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
jcm_albiñana_2022.pdf | Artículo principal | 1,45 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
6
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
6
checked on 28-feb-2024
Page view(s)
38
checked on 23-abr-2024
Download(s)
128
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons